Market Place
Sourcing Support
Vertex inks long-term access deal for CF meds in Englan
22 Jun 2024 //
FIERCE PHARMA
Vertex Receives CHMP Positive Opinion for KALYDECO® for Cystic Fibrosis
23 Feb 2024 //
BUSINESSWIRE
Vertex`s sales of Trikafta hit $8.9B thanks to label expansion
06 Feb 2024 //
FIERCE PHARMA
Vertex meets own cystic fibrosis record with next-gen treatment
06 Feb 2024 //
FIERCE BIOTECH
Vertex Announces EMA Validation for MAA Extension for KAFTRIO
24 Nov 2023 //
BUSINESSWIRE
EC Approves KAFTRIO® in Combination With Ivacaftor
23 Nov 2023 //
BUSINESSWIRE
NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds
07 Nov 2023 //
FIERCE PHARMA
Vertex Receives CHMP Positive Opinion for KAFTRIO
15 Sep 2023 //
BUSINESSWIRE
European Commission Approves ORKAMBI for Cystic Fibrosis
05 Jul 2023 //
BUSINESSWIRE
Vertex secures FDA clearance for infants’ cystic fibrosis therapy
05 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
27 Apr 2023 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With CF
26 Apr 2023 //
BUSINESSWIRE
Vertex Announces Health Canada Market Authorization for ORKAMBI& in Children
11 Apr 2023 //
BIOSPACE
In Cystic Fibrosis Failure, Eloxx Sees Silver Lining for Alport Syndrome
16 Sep 2022 //
BIOSPACE
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq
05 Sep 2022 //
NASDAQ
Vertex Announces U.S. FDA Approval for ORKAMBI in Children
03 Sep 2022 //
BUSINESSWIRE
FDA confirms Paragraph IV Patent Litigation for Ivacaftor
13 Jun 2022 //
FDA
Lupin gets US FDA nod for generic drug
09 Jun 2022 //
EXPRESS PHARMA
Lupin`s Generic Ivacaftor Receives Approval in the US
07 Jun 2022 //
FDA
Health Canada Grants Marketing Authorization for TRIKAFTA
20 Apr 2022 //
BUSINESSWIRE
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA
26 Mar 2022 //
BUSINESSWIRE
European Commission approves cystic fibrosis treatment for six to 11-year-olds
11 Jan 2022 //
PHARMATIMES
EMA recommends approval of Kaftrio + ivacaftor in 6-11Y age of children with CF
15 Nov 2021 //
PHARMABIZ
Health Canada accepts Priority Review of Vertex`s sNDA for KALYDECO in CF
22 Sep 2021 //
BIOSPACE
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance
17 Sep 2021 //
BIOSPACE
Health Canada approves Vertex Pharma’s Prkalydeco to treat infants with CF
27 Aug 2021 //
PHARMABIZ
Vertex Announces Publication in The New England Journal of Medicine
26 Aug 2021 //
BUSINESSWIRE
Vertex Announces National Reimbursement Agreement in France for KAFTRIO
28 Jun 2021 //
BUSINESSWIRE
Health Canada Grants Marketing Authorization for TRIKAFTA
18 Jun 2021 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA
09 Jun 2021 //
BUSINESSWIRE
Vertex Announces European Commission Approval for SYMKEVI®
26 Nov 2020 //
BUSINESSWIRE
Vertex’s Kalydeco scores another label extension in EU
06 Nov 2020 //
PHARMATIMES
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor)
05 Nov 2020 //
BUSINESSWIRE
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor)
04 Nov 2020 //
PHARMIWEB
FDA Approves Kalydeco for Infants as Young as 4 Months
25 Sep 2020 //
CFF
Vertex gets FDA nod to Kalydeco for cystic fibrosis in 4 to 6-month infants
25 Sep 2020 //
SEEKING ALPHA
FDA Approves KALYDECO® as 1st & Only CFTR Modulator to Treat Eligible Infants
25 Sep 2020 //
BUSINESSWIRE
Vertex to Present New Data at Virtual Cystic Fibrosis Conferences
24 Sep 2020 //
BUSINESSWIRE
Positive Ph3 Study TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
20 Jul 2020 //
BIOSPACE
Vertex Announces Expansion of Reimbursement Agreement With NHS KAFTRIO ®
30 Jun 2020 //
PRESS RELEASE
EMA recommends eight new medicines, refuses one
27 Jun 2020 //
RAPS
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)
26 Jun 2020 //
BUSINESSWIRE
EU expands reach of Vertex` CF drug Kalydeco
09 Jun 2020 //
PHARMATIMES
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor)
01 May 2020 //
BUSINESSWIRE
Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI®
20 Apr 2020 //
BUSINESSWIRE
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
27 Nov 2019 //
RAPS
Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK
14 Nov 2019 //
REUTERS
Vertex`s cystic fibrosis portfolio to be made available across Northern
13 Nov 2019 //
PHARMAFILE
‘Impressive’ results for Trikafta in cystic fibrosis
02 Nov 2019 //
PHARMATIMES
Vertex is `humming` with triple combo launch Trikafta underway: analyst
31 Oct 2019 //
FIERCE PHARMA
Vertex inks agreement with NHS England for access to all licensed CF medicines
30 Oct 2019 //
BUSINESSWIRE
Spanish Government Approves National Reimbursement of ORKAMBI®
21 Oct 2019 //
BUSINESSWIRE
Vertex Receives European CHMP Positive Opinion for KALYDECO®
18 Oct 2019 //
BUSINESSWIRE
Labour Party takes aim at pharma, calls attention to Orkambi row
26 Sep 2019 //
PMLIVE
U.K.Labour Party wants government to build its own manufacturing
25 Sep 2019 //
FIERCE PHARMA
Vertex deal for Scotland — no deal for England
13 Sep 2019 //
ENDPTS
Vertex sinks on reports of deaths of patients taking cystic fibrosis drug
28 Aug 2019 //
STATNEWS
FDA Grants Priority Review to Vertex’s 1st Triple Combo for CF
27 Aug 2019 //
CYSTICFIBROSISNEWS TODAY
FDA Accepts New Drug Application for VX-445 (Elexacaftor) Tezacaftor & Ivacaftor
20 Aug 2019 //
BUSINESSWIRE
